639 related articles for article (PubMed ID: 27169844)
21. Outcomes after resection of locally advanced or borderline resectable pancreatic cancer after neoadjuvant therapy.
Barugola G; Partelli S; Crippa S; Capelli P; D'Onofrio M; Pederzoli P; Falconi M
Am J Surg; 2012 Feb; 203(2):132-9. PubMed ID: 21824596
[TBL] [Abstract][Full Text] [Related]
22. FDG-PET predicts treatment efficacy and surgical outcome of pre-operative chemoradiation therapy for resectable and borderline resectable pancreatic cancer.
Akita H; Takahashi H; Ohigashi H; Tomokuni A; Kobayashi S; Sugimura K; Miyoshi N; Moon JH; Yasui M; Omori T; Miyata H; Ohue M; Fujiwara Y; Yano M; Ishikawa O; Sakon M
Eur J Surg Oncol; 2017 Jun; 43(6):1061-1067. PubMed ID: 28389044
[TBL] [Abstract][Full Text] [Related]
23. Survival benefit of neoadjuvant therapy in patients with non-metastatic pancreatic ductal adenocarcinoma: A propensity matching and intention-to-treat analysis.
Sugimoto M; Takahashi N; Farnell MB; Smyrk TC; Truty MJ; Nagorney DM; Smoot RL; Chari ST; Carter RE; Kendrick ML
J Surg Oncol; 2019 Nov; 120(6):976-984. PubMed ID: 31452208
[TBL] [Abstract][Full Text] [Related]
24. Reassessment of the clinical significance of portal-superior mesenteric vein invasion in borderline resectable pancreatic cancer.
Hoshimoto S; Hishinuma S; Shirakawa H; Tomikawa M; Ozawa I; Wakamatsu S; Hoshi S; Hoshi N; Hirabayashi K; Ogata Y
Eur J Surg Oncol; 2017 Jun; 43(6):1068-1075. PubMed ID: 28427822
[TBL] [Abstract][Full Text] [Related]
25. Significance of Glucose Transporter Type 1 (GLUT-1) Expression in the Therapeutic Strategy for Pancreatic Ductal Adenocarcinoma.
Kurahara H; Maemura K; Mataki Y; Sakoda M; Iino S; Kawasaki Y; Arigami T; Mori S; Kijima Y; Ueno S; Shinchi H; Natsugoe S
Ann Surg Oncol; 2018 May; 25(5):1432-1439. PubMed ID: 29404819
[TBL] [Abstract][Full Text] [Related]
26. A gene expression signature for predicting response to neoadjuvant chemoradiotherapy in pancreatic ductal adenocarcinoma.
Nishiwada S; Sho M; Cui Y; Yamamura K; Akahori T; Nakagawa K; Nagai M; Nakamura K; Takagi T; Ikeda N; Li W; Baba H; Goel A
Int J Cancer; 2021 Feb; 148(3):769-779. PubMed ID: 32895958
[TBL] [Abstract][Full Text] [Related]
27. Validation of the Anatomical and Biological Definitions of Borderline Resectable Pancreatic Cancer According to the 2017 International Consensus for Survival and Recurrence in Patients with Pancreatic Ductal Adenocarcinoma Undergoing Upfront Surgery.
Lee B; Yoon YS; Kang M; Park Y; Lee E; Jo Y; Lee JS; Lee HW; Cho JY; Han HS
Ann Surg Oncol; 2023 Jun; 30(6):3444-3454. PubMed ID: 36695994
[TBL] [Abstract][Full Text] [Related]
28. Neoadjuvant therapy versus upfront surgery for resected pancreatic adenocarcinoma: A nationwide propensity score matched analysis.
de Geus SW; Eskander MF; Bliss LA; Kasumova GG; Ng SC; Callery MP; Tseng JF
Surgery; 2017 Mar; 161(3):592-601. PubMed ID: 28341441
[TBL] [Abstract][Full Text] [Related]
29. Total Neoadjuvant Therapy With FOLFIRINOX Followed by Individualized Chemoradiotherapy for Borderline Resectable Pancreatic Adenocarcinoma: A Phase 2 Clinical Trial.
Murphy JE; Wo JY; Ryan DP; Jiang W; Yeap BY; Drapek LC; Blaszkowsky LS; Kwak EL; Allen JN; Clark JW; Faris JE; Zhu AX; Goyal L; Lillemoe KD; DeLaney TF; Fernández-Del Castillo C; Ferrone CR; Hong TS
JAMA Oncol; 2018 Jul; 4(7):963-969. PubMed ID: 29800971
[TBL] [Abstract][Full Text] [Related]
30. Covered self-expandable metal stent deployment promises safe neoadjuvant chemoradiation therapy in patients with borderline resectable pancreatic head cancer.
Kubota K; Sato T; Watanabe S; Hosono K; Kobayashi N; Mori R; Taniguchi K; Matsuyama R; Endo I; Nakajima A
Dig Endosc; 2014 Jan; 26(1):77-86. PubMed ID: 23551230
[TBL] [Abstract][Full Text] [Related]
31. Factors Predicting Response, Perioperative Outcomes, and Survival Following Total Neoadjuvant Therapy for Borderline/Locally Advanced Pancreatic Cancer.
Truty MJ; Kendrick ML; Nagorney DM; Smoot RL; Cleary SP; Graham RP; Goenka AH; Hallemeier CL; Haddock MG; Harmsen WS; Mahipal A; McWilliams RR; Halfdanarson TR; Grothey AF
Ann Surg; 2021 Feb; 273(2):341-349. PubMed ID: 30946090
[TBL] [Abstract][Full Text] [Related]
32. Changes and prognostic impact of inflammatory nutritional factors during neoadjuvant chemoradiotherapy for patients with resectable and borderline resectable pancreatic cancer.
Oshima M; Okano K; Suto H; Ando Y; Kamada H; Masaki T; Takahashi S; Shibata T; Suzuki Y
BMC Gastroenterol; 2020 Dec; 20(1):423. PubMed ID: 33317455
[TBL] [Abstract][Full Text] [Related]
33. Intraoperative Radiotherapy in the Era of Intensive Neoadjuvant Chemotherapy and Chemoradiotherapy for Pancreatic Adenocarcinoma.
Keane FK; Wo JY; Ferrone CR; Clark JW; Blaszkowsky LS; Allen JN; Kwak EL; Ryan DP; Lillemoe KD; Fernandez-Del Castillo C; Hong TS
Am J Clin Oncol; 2018 Jun; 41(6):607-612. PubMed ID: 27740973
[TBL] [Abstract][Full Text] [Related]
34. Modified Appleby procedure for borderline resectable/locally advanced distal pancreatic adenocarcinoma: A major procedure for selected patients.
Cesaretti M; Abdel-Rehim M; Barbier L; Dokmak S; Hammel P; Sauvanet A
J Visc Surg; 2016 Jun; 153(3):173-81. PubMed ID: 26775202
[TBL] [Abstract][Full Text] [Related]
35. Neoadjuvant Chemotherapy in Pancreatic Cancer: An Appraisal of the Current High-Level Evidence.
Müller PC; Frey MC; Ruzza CM; Nickel F; Jost C; Gwerder C; Hackert T; Z'graggen K; Kessler U
Pharmacology; 2021; 106(3-4):143-153. PubMed ID: 32966993
[TBL] [Abstract][Full Text] [Related]
36. Prediction of local tumor control and recurrence-free survival in patients with pancreatic cancer undergoing curative resection after neoadjuvant chemoradiotherapy.
Suto H; Okano K; Oshima M; Ando Y; Matsukawa H; Takahashi S; Shibata T; Kamada H; Masaki T; Suzuki Y
J Surg Oncol; 2022 Aug; 126(2):292-301. PubMed ID: 35289928
[TBL] [Abstract][Full Text] [Related]
37. The immunological impact of preoperative chemoradiotherapy on the tumor microenvironment of pancreatic cancer.
Okubo S; Suzuki T; Hioki M; Shimizu Y; Toyama H; Morinaga S; Gotohda N; Uesaka K; Ishii G; Takahashi S; Kojima M
Cancer Sci; 2021 Jul; 112(7):2895-2904. PubMed ID: 33931909
[TBL] [Abstract][Full Text] [Related]
38. Neoadjuvant chemoradiotherapy followed by D2 gastrectomy in locally advanced gastric cancer.
Kim MS; Lim JS; Hyung WJ; Lee YC; Rha SY; Keum KC; Koom WS
World J Gastroenterol; 2015 Mar; 21(9):2711-8. PubMed ID: 25759540
[TBL] [Abstract][Full Text] [Related]
39. Prolonged Neoadjuvant Therapy for Locally Advanced Pancreatic Cancer.
Eguchi H; Yamada D; Iwagami Y; Gotoh K; Kawamoto K; Wada H; Asaoka T; Noda T; Takeda Y; Tanemura M; Sakai D; Satoh T; Kudo T; Isohashi F; Mori M; Doki Y
Dig Surg; 2018; 35(1):70-76. PubMed ID: 28482348
[TBL] [Abstract][Full Text] [Related]
40. Impact of Neoadjuvant Therapy in Resected Pancreatic Ductal Adenocarcinoma of the Pancreatic Body or Tail on Surgical and Oncological Outcome: A Propensity-Score Matched Multicenter Study.
Lof S; Korrel M; van Hilst J; Alseidi A; Balzano G; Boggi U; Butturini G; Casadei R; Dokmak S; Edwin B; Falconi M; Keck T; Malleo G; de Pastena M; Tomazic A; Wilmink H; Zerbi A; Besselink MG; Abu Hilal M;
Ann Surg Oncol; 2020 Jun; 27(6):1986-1996. PubMed ID: 31848815
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
